Several small molecule drugs identified using computational methods have been applied to breast cancer treatment, including alpelisib, a phosphatidylinositol-3 kinase alpha inhibitor50, talazoparib tosylate, a poly (ADP-ribose) polymerase inhibitor51, neratinib maleate, a receptor tyrosine kinase, human epidermal growth factor receptor 2, and human EGFR inhibitor, and ribociclib, a cyclin-dependent kinase (CDK) inhibitor. Here, NTRK1 is linked to breast carcinoma.